BC Extra | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

Cellestia is developing what could be a first-in-class small molecule that prevents assembly of transcription factor complexes that activate oncogene expression, and has raised CHF20 million ($20.3 million) in a B round that’ll enable completion...
BC Innovations | Jun 19, 2019
Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Blocking hyaluronan synthesis, including via inhibition of HAS2 or its downstream effector NOTCH1, could help treat liver fibrosis. In hepatitis B, hepatitis C and NASH patients,...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Week In Review | Dec 14, 2018
Clinical News

SanBio’s SB623 meets in Phase II for TBI

SanBio Co. Ltd. (Tokyo:4592) reported Nov. 1 that intracranial SB623 cells met the primary endpoint of improving motor function as measured by the change from baseline in Fugl-Meyer Motor Scale (FMMS) score at 24 weeks...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Oct 18, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting Notch 1 could help treat metastatic medulloblastoma. In primary tumor samples from medulloblastoma patients, levels of Notch 1 were higher in patients with metastases than...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Gastrointestinal; cancer

INDICATION: Adenomatous polyps; colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting JAG1 could help treat familial adenomatous polyposis (FAP) and Notch 1-positive, MFNG-negative colorectal cancers. In Notch 1-positive tumor samples from 198...
BC Innovations | Jan 18, 2018
Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications...
BC Innovations | Jul 13, 2017
Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
Items per page:
1 - 10 of 88